PSI selects goBalto's site ID cloud-based software to speed up trials

By Staff Reporter

- Last updated on GMT

PSI selects goBalto's site ID cloud-based software to speed up trials
PSI has selected goBalto’s cloud-based Select module management system to help manage a multi-country Phase II clinical trial.

The Swiss contract research organisation (CRO) has chosen goBalto's end-to-end solution to assist with site identification, feasibility assessment and selection of sites for the study.

“Select simplifies the process of finding investigative sites by ensuring optimal fit and its integrated workflows allow our globally dispersed clinical research teams to collaborate in real-time,”​ Kirill Soldatov, director of process improvement at PSI, said in a statement.

“Investigative sites can then be quickly setup to enrol trial subjects using Activate.”

Activate is goBalto's clinical trial workflow software, already being used by PSI, and like Select is entirely cloud-based.

PSI is the latest CRO to select goBalto’s software. In December last year​, ICON opted for the Activate platform for all global studies spanning more than 50 countries in an effort to speed-up initiation of its clinical trials.

At the time, ICON VP Marie Keegan said: “Accelerating study startup timelines is a key component of our ICONIK Informatics Hub strategy which combines industry leading technologies with best practices to help our clients take time and cost from their development programs.

“Following a comprehensive review of our study startup activities, we adopted a range of new processes and procedures that have streamlined our site activation. We supplemented this with the capabilities of goBalto's Activate and Analyze to drive our study startup process, and are seeing significant positive impact on cycle time, quality and productivity as a result.”

More recently​, Australian CRO CMIC Holdings selected the Activate platform for multi-country studies being conducted in Malaysia, Singapore, Taiwan, Philippines, Thailand, Japan, and South Korea.

Related news

Show more

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers